Abstract:The NLRP3 inflammasome is a critical component of innate immunity, which defends internal and external threats. However, inappropriate activation of the NLRP3 inflammasome induces various human diseases. In this study, we discovered and synthesized a series of tetrahydroquinoline inhibitors of NLRP3 inflammasome. Among these analogues, compound 6 exhibited optimal NLRP3 inhibitory activity. In vitro studies indicated that compound 6 directly bound to the NACHT domain of NLRP3 but not to protein pyrin domain (PYD) or LRR domain, inhibited NLRP3 ATPase activity, and blocked ASC oligomerization, thereby inhibiting NLRP3 inflammasome assembly and activation. Compound 6 specifically inhibited the NLRP3 inflammasome activation, but had no effect on the activation of NLRC4 or AIM2 inflammasomes. Furthermore, in the dextran sulfate sodium (DSS)-induced colitis mouse model, compound 6 exhibited significant anti-inflammatory activity through inhibiting NLRP3 inflammasome in vivo. Therefore, our study provides a potent NLRP3 inflammasome inhibitor, which deserves further structural optimization as a novel therapeutic candidate for NLRP3-driven diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01924?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01924</a>.1H NMR, 13C NMR, and HPLC spectra analysis of all synthetic compounds; amino acid sequences of NLRP3 PYD domain, NACHT domain, and LRR domain; pharmacophore generation; pharmacophore and docking screening; small molecules in training set and testing set; and the activity tests of selected ligands (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_002.csv">CSV</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_003.pdf">PDF</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_004.xls">XLS</a>)This article has not yet been cited by other publications.

Discovery of Autophagy-tethering Compounds As Potent NLRP3 Degraders for IBD Immunotherapy

Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis

Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

The research progression of direct NLRP3 inhibitors to treat inflammatory disorders

Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen

Synthesis and Anti-Inflammatory Bowel Disease Activity of Pterostilbene Derivatives

Discovery of Novel 2,3-Dihydro-1h-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon As a Potential Therapy for Colitis.

Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis

Identification of Tubocapsanolide A as a novel NLRP3 inhibitor for potential treatment of colitis

The regulation of NLRP3 inflammasome activation by CCDC50-mediated autophagy

Discovery and Optimization of 4-Oxo-2-thioxo-thiazolidinones As NOD-like Receptor (NLR) Family, Pyrin Domain-Containing Protein 3 (NLRP3) Inhibitors.

Deep-Learning-Driven Discovery of SN3-1, a Potent NLRP3 Inhibitor with Therapeutic Potential for Inflammatory Diseases

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Development of the First-in-Class Degrader of NLRP3

Inhibition of NLRP3 Attenuates Sodium Dextran Sulfate-Induced Inflammatory Bowel Disease Through Gut Microbiota Regulation.

Discovery of NLRP3 Inhibitors Using Machine Learning: Identification of a Hit Compound to Treat NLRP3 Activation-Driven Diseases.

Novel Sulfonylurea-Based NLRP3 Inflammasome Inhibitor for Efficient Treatment of Nonalcoholic Steatohepatitis, Endotoxic Shock, and Colitis.

NLRP3: A Promising Therapeutic Target for Inflammatory Bowel Disease.